Genentech moving away from Caremark
Bergen Brunswig accounted for 14% of Genentech sales in 1999 ($200 mil.), up from 11% in 1998. Cardinal represented 13% of sales ($180 mil.), up from 11%. Caremark represented less than 10% of revenues in 1999, down from 10% in 1998 and 14% in 1997. The change in part reflects the diminishing importance of human growth hormone to Genentech. At its peak, an exclusive growth hormone supply agreement with Caremark represented more than 25% of Genentech revenues
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth